GB201912008D0 - Antibody - Google Patents

Antibody

Info

Publication number
GB201912008D0
GB201912008D0 GBGB1912008.8A GB201912008A GB201912008D0 GB 201912008 D0 GB201912008 D0 GB 201912008D0 GB 201912008 A GB201912008 A GB 201912008A GB 201912008 D0 GB201912008 D0 GB 201912008D0
Authority
GB
United Kingdom
Prior art keywords
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1912008.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GBGB1912008.8A priority Critical patent/GB201912008D0/en
Publication of GB201912008D0 publication Critical patent/GB201912008D0/en
Priority to PCT/GB2020/051965 priority patent/WO2021032966A1/en
Ceased legal-status Critical Current

Links

GBGB1912008.8A 2019-08-21 2019-08-21 Antibody Ceased GB201912008D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1912008.8A GB201912008D0 (en) 2019-08-21 2019-08-21 Antibody
PCT/GB2020/051965 WO2021032966A1 (en) 2019-08-21 2020-08-17 Detection of a-beta oligomers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1912008.8A GB201912008D0 (en) 2019-08-21 2019-08-21 Antibody

Publications (1)

Publication Number Publication Date
GB201912008D0 true GB201912008D0 (en) 2019-10-02

Family

ID=68099564

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1912008.8A Ceased GB201912008D0 (en) 2019-08-21 2019-08-21 Antibody

Country Status (2)

Country Link
GB (1) GB201912008D0 (en)
WO (1) WO2021032966A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PL2246427T3 (en) * 2008-02-08 2017-06-30 Immunas Pharma, Inc. Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof
PL2147594T3 (en) 2008-06-27 2014-04-30 Merus Nv Antibody producing non-human mammals
ES2603559T5 (en) 2010-02-08 2021-02-22 Regeneron Pharma Mouse common light chain
AU2017299858A1 (en) * 2016-07-18 2019-02-07 Promis Neurosciences, Inc. Antibodies to amyloid beta

Also Published As

Publication number Publication date
WO2021032966A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-sirpα antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-tigit antibodies
IL279352A (en) Il-11ra antibodies
IL280013A (en) Anti-il36r antibodies
IL278010A (en) Galectin-10 antibodies
IL289112A (en) Anti-tigit antibodies
IL277030A (en) Antibodies
GB202110263D0 (en) Anti-btla antibodies
IL291068A (en) Anti-cd73 antibodies
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
IL284584A (en) Anti-tigit antibodies
ZA202108836B (en) Anti-epha4 antibody
IL281594A (en) Anti-klrg1 antibodies
GB201817172D0 (en) Antibody
GB201905150D0 (en) Ant-ige antibodies
GB2581174B (en) Antibodies against hEPCR
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB201919062D0 (en) Antibody
GB201912008D0 (en) Antibody
SG11201913540VA (en) Anti-Podoplanin Antibody

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)